Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has released an update to notify the public and investors about an entry into a material definitive agreement.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shuttle Pharmaceuticals Holdings, Inc. has acquired the rights to the promising “PSMA-Boron” Invention, aimed at enhancing prostate cancer diagnosis and treatment, through agreements with inventors Alan Kozikowksi, Werner Tueckmantel, and Dr. Anatoly Dritschilo. The inventors will receive initial payments and potential royalties from future commercialization. This acquisition marks a strategic move for the company, eyeing advancement in cancer theranostics, subject to successful research and regulatory approvals. The company’s forward-looking statements indicate plans for the Invention’s development but acknowledge the typical risks and uncertainties inherent in such innovative medical ventures.
For further insights into SHPH stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
